PRESENTERS

Julie Rodman, OD, MS, FAAO 
Nova Southeastern University
Fort Lauderdale, FL 

Deepak Sambhara, MD 
Eye Clinic of Wisconsin 
Wausau, WI
 

Join us for a panel discussion among eyecare providers including questions such as:

• What is GA and what does a typical patient look like?
• What is the best way to detect GA in my practice and when should I refer to a specialist?
• What is the efficacy and safety profile of SYFOVRE and how does it work?

INDICATION

SYFOVRE^® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS 

• SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

WARNINGS AND PRECAUTIONS

• Endophthalmitis and Retinal Detachments

  • Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

• Retinal Vasculitis and/or Retinal Vascular Occlusion

  • Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.

• Neovascular AMD

  • In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.

• Intraocular Inflammation

  • In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.

• Increased Intraocular Pressure

  • Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS 

• Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

Please see full Prescribing Information for more information.

This promotional event is presented by Apellis Pharmaceuticals, Inc. and all faculty are paid consultants of Apellis Pharmaceuticals, Inc. This program is intended for US eyecare professionals only. Guests and spouses may not attend this program and no CME credits are offered. A meal will be provided during this promotional program. In accordance with the Federal Physician Payment Sunshine Statute and any applicable state reporting laws, the value of the food and beverage provided may be disclosed to CMS and any applicable state agencies.

APELLIS^®, SYFOVRE^® and their respective logos are registered trademarks of Apellis Pharmaceuticals, Inc. 
Other trademarks referenced herein are the property of their respective owners.
© 2024 Apellis Pharmaceuticals, Inc. All rights reserved. 04/24 US-PEGGA-2300232  v2.0

Sponsored by

Brought to you by